Revenue Performance - In Q1 2025, Dexcom reported worldwide revenue of $1.036 billion, a 12% increase from $921 million in Q1 2024[4] - U.S. revenue grew 15% year-over-year to $750.5 million, while international revenue increased by 7% to $285.5 million[24] - Total revenue for the three months ended March 31, 2025, was $1,036.0 million, representing a year-over-year growth of 12% compared to $921.0 million in 2024[26] - Sensor and other revenue increased to $997.2 million, a 17% growth year-over-year, accounting for 96% of total revenue[26] - Hardware revenue decreased to $38.8 million, reflecting a decline of 42% year-over-year, making up 4% of total revenue[26] Profitability Metrics - GAAP gross profit for Q1 2025 was $589 million, representing 56.9% of revenue, down from 61.0% in Q1 2024[4] - Non-GAAP gross profit was $596.2 million, or 57.5% of revenue, compared to 61.8% in Q1 2024[5] - GAAP operating income was $133.7 million, or 12.9% of revenue, up from $101.1 million, or 11.0% of revenue, in Q1 2024[7] - GAAP net income for Q1 2025 was $105.4 million, down from $146.4 million in Q1 2024, while non-GAAP net income was $127.7 million compared to $128.2 million[28] - Adjusted EBITDA for the three months ended March 31, 2025, was $230.4 million, an increase from $220.9 million in the same period last year[27] - GAAP diluted net income per share for Q1 2025 was $0.27, down from $0.36 in Q1 2024, while non-GAAP diluted net income per share remained stable at $0.32[28] Financial Management - Dexcom's cash and cash equivalents totaled $2.70 billion as of March 31, 2025, providing significant financial flexibility[10] - The company announced a $750 million share repurchase program alongside its Q1 results[3] - Interest expense decreased to $(23.8) million in Q1 2025 from $(31.7) million in Q1 2024, indicating improved financial management[27] Future Outlook - The company expects 2025 revenue to reach approximately $4.60 billion, reflecting a 14% growth[6] - Non-GAAP operating margin is projected to be around 21% for 2025[6] Product Development - Dexcom received FDA clearance for the Dexcom G7 15 Day System shortly after the end of the quarter[5] Investment Performance - The company reported a loss from equity investments of $4.2 million in Q1 2025, with no such loss reported in Q1 2024[27] Operational Focus - The company continues to focus on organic revenue growth and has excluded certain non-recurring items from its non-GAAP financial measures to provide clearer insights into operational performance[30][34]

Core Insights - DexCom (DXCM) is expected to report quarterly earnings of $0.33 per share, reflecting a 3.1% increase year-over-year, with revenues projected at $1.02 billion, indicating a 10.3% year-over-year growth [1] Revenue Estimates - The consensus estimate for 'Revenue- Hardware' is $38.39 million, showing a significant decline of 42.4% from the previous year [4] - 'Revenue- Sensor and other' is projected at $978.78 million, representing a year-over-year increase of 14.6% [4] - 'Revenue- United States' is expected to reach $709.42 million, indicating an 8.6% increase compared to the same quarter last year [4] - 'Revenue- International' is anticipated to be $303.93 million, reflecting a 13.5% year-over-year growth [5] Market Performance - Over the past month, DexCom shares have increased by 4.2%, contrasting with a decline of 0.8% in the Zacks S&P 500 composite [6] - DexCom currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [6]

Core Viewpoint - DexCom, Inc. is set to release its first-quarter 2025 results on May 1, with expectations of revenue growth and potential challenges ahead [1][3][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.02 billion, reflecting a 10.3% increase from the previous year [3]. - The consensus estimate for earnings is 33 cents per share, indicating a 3.1% year-over-year growth [3]. - In the last reported quarter, DexCom's earnings missed estimates by 10% but outperformed in three of the last four quarters, with an average surprise of 5.86% [1]. Market Dynamics - DexCom's performance is bolstered by an expanded U.S. prescriber base and improved coverage by major pharmacy benefit managers (PBMs) [5]. - The company has seen a record number of new patient starts and added 50,000 new clinicians in 2024, indicating strong commercial execution [6]. - U.S. revenues improved by 4% year-over-year in the fourth quarter, following a decline in the third quarter [7]. International Expansion - The international segment grew by 17% year-over-year in the last quarter, driven by the launch of G7 in Australia and coverage for Dexcom ONE+ in France and New Zealand [7][8]. - The return to growth in Japan, aided by a new sales structure, is a significant highlight [8]. Product Development - Stelo, an over-the-counter continuous glucose monitor, has gained traction with over 140,000 users in its first four months [8]. - DexCom plans to enhance Stelo's adoption through product iterations and partnerships, including integration with Oura Ring for comprehensive health monitoring [9]. Financial Outlook - DexCom projects full-year 2025 revenue of $4.6 billion, representing organic growth of 14% [10]. - The company anticipates continued margin improvement as it converts its installed base to G7 and scales manufacturing [10]. - DexCom holds a strong cash position of $2.58 billion, providing financial flexibility for strategic initiatives [11].

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and ...

Core Insights - DexCom, Inc. has received FDA clearance for its G7 Continuous Glucose Monitoring (CGM) system, which is the longest-lasting and most accurate CGM approved in the U.S. for individuals over 18 with diabetes [1][2] Company Developments - The G7 system features a 15-day wear duration, improved accuracy with a Mean Absolute Relative Difference of 8%, and enhanced user experience through a redesigned mobile app [6][7] - The FDA clearance is expected to boost DexCom's market position, allowing for an expanded customer base and increased recurring revenue from sensors [4] - DexCom's current market capitalization stands at $26.21 billion [5] Competitive Landscape - The G7 CGM system's 15-day wear time aligns it with Abbott's Libre 2 CGM system, enhancing its competitive edge in the diabetes technology market [4][9] - DexCom is also pursuing partnerships with insulin pump manufacturers to ensure compatibility with automated insulin delivery systems [9] Industry Outlook - The global digital diabetes management market is projected to grow from $18.9 billion in 2023 to $35.8 billion by 2028, reflecting a compound annual growth rate of 13.6% [11] - Key drivers of this growth include advancements in diabetes care solutions, the popularity of connected devices, and the adoption of cloud-based solutions [12]

Core Insights - The U.S. FDA has approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for individuals over 18 with diabetes, featuring an overall Mean Absolute Relative Difference (MARD) of 8.0% [1] - The Dexcom G7 15 Day is expected to launch in the U.S. in the second half of 2025 and is designed to be compatible with automated insulin delivery systems [3] Product Features - The Dexcom G7 15 Day is the longest-lasting CGM system with a wear time of 15.5 days, allowing for easier glucose management with fewer monthly sensors and reduced waste [5] - It is the only waterproof CGM available and offers hands-free management by connecting directly to the patient's Apple Watch [5] - The system includes automated activity logging, simplified meal logging, and medication logging to help users understand the impact of activity, food, and medications on glucose levels in real time [5] - A 12-hour grace period is provided to replace finished sensors, ensuring a seamless transition between sessions [5] - The mobile app integrates with Dexcom Clarity, allowing users to view glucose patterns, trends, and statistics through interactive reports [5] - Users can remotely share glucose numbers with caregivers and loved ones for added support and peace of mind, along with enhanced and customizable alert settings for improved discretion [5]

What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy. Unless a company's investment thesis has changed because of recent developments, market downturns aren't a good enough reason for most investors to sell.For those who can afford it without blowing their budget, it's actually a great idea to pick up shares of top companies on the dip during a correction. With that in mind, here are two excellent growth-oriented companies to buy in the ong ...

Core Insights - DexCom has entered a licensing and data partnership with Nanowear to utilize glucose data from its G7 Continuous Glucose Monitoring Systems alongside Nanowear's cardiovascular biomarkers for investigational purposes [1][2] Group 1: Partnership and Integration - The collaboration enhances DexCom's leadership in CGM integration and aligns with its vision to expand CGM applications beyond diabetes management, emphasizing the potential for continuous metabolic health monitoring [2] - The integration of DexCom G7 CGM data into Nanowear's SimpleSense platform creates a self-administered cardiometabolic assessment tool, offering real-time diagnostic insights by synchronizing glucose data with cardiovascular biomarkers [3] Group 2: Market Demand and Health Insights - Cardiometabolic health issues, such as obesity and hypertension, are significant contributors to morbidity in the U.S., with only 6.8% of Americans having optimal cardiometabolic health, highlighting the need for innovative solutions [4] - The partnership allows DexCom to provide insights into the cardiometabolic effects of new therapeutics, catering to pharmaceutical and biotech sectors seeking novel assessment solutions [4] Group 3: Innovation in Clinical Research - The ability to conduct home-based, self-administered assessments represents a shift in clinical research, allowing for continuous monitoring that traditional assessments lack [5] - By integrating with Nanowear's AI-driven diagnostic tools, DexCom aids pharmaceutical and biotechnology companies in evaluating drug safety and efficacy with greater detail [5] Group 4: Competitive Landscape - DexCom faces competition from Abbott's FreeStyle Libre CGM device, which offers automatic glucose readings every minute and a longer wear time of 15 days compared to DexCom's 10-day wear time for G7 [9][10] - Recent FDA warnings regarding manufacturing practices may delay DexCom's approval for a 15-day G7 sensor, increasing competitive pressure from FreeStyle Libre [10]

Core Viewpoint - DexCom (DXCM) is under regulatory scrutiny from the FDA due to a warning letter that may impact the approval of its upcoming 15-day G7 continuous glucose monitor (CGM) [1][2][10] Regulatory Concerns - The FDA's warning letter highlighted multiple violations, including the failure to submit a premarket notification for significant modifications to its sensors, which poses increased risks for users [1][2] - Concerns were raised regarding Dexcom's testing procedures for glucose and acetaminophen concentrations in both G6 and G7 CGMs, as well as issues related to dissolved oxygen content values in G6 sensors [2] Market Impact - Following the warning letter, DXCM shares fell by 1.9% on March 25, with a year-to-date decline of 7.2%, compared to a 2% decline in the industry and a 2.1% decrease in the S&P 500 Index [3] - A potential delay in obtaining clearance for the G7 sensor could result in a loss of market share, especially against competitors like Abbott's Libre, which has a longer wearable life [4] Sales and Distribution - Although the warning letter does not mandate an immediate recall, it may cause delays in regulatory approvals, and the company has halted commercial distribution of G7 with faulty sensors, potentially impacting first-quarter sales [5][6] Company Response - Dexcom has reaffirmed its commitment to regulatory standards and is working with the FDA to resolve issues, although the FDA has deemed the company's response as inadequate [9] - Despite the regulatory challenges, Dexcom remains confident that the warning letter will not materially affect the approval or launch of the 15-day G7 CGM, expected in the second half of the year [10]

Core Insights - DexCom, Inc. has introduced new data for its G7 15-day continuous glucose monitoring (CGM) sensor, showcasing a mean absolute relative difference (MARD) of 8.0%, positioning it as the most accurate CGM in the market [1] - The G7 sensor's extended wear time and enhanced connectivity are expected to revolutionize diabetes management, particularly for Type 2 diabetes patients [3][4] - The company anticipates FDA approval for the G7 sensor by the second quarter of 2025, with a potential launch in the latter half of the year [5] Product Features and Market Position - The G7 sensor offers a 15-day wear duration, an improvement over the previous 10-day version, which reduces replacement frequency and overall costs for users [4] - DexCom is recognized as the most connected CGM brand globally, with new integration capabilities for devices like Omnipod 5 and NovoPen [10] - The company is leading the CGM market by driving innovation, expanding insurance coverage, and advocating for broader access to diabetes technology [3] Industry Trends and Healthcare Professional Insights - A survey indicates that 52% of healthcare professionals believe CGMs and diabetes education will be more crucial than new medications in managing Type 2 diabetes over the next decade [6] - There is strong support among healthcare professionals for CGM access among insulin users, with 96% advocating for multiple daily insulin injection users to have access [7] - Despite increasing recognition of CGMs, challenges such as funding constraints and restrictive eligibility criteria remain [8] Insurance Coverage and Accessibility - Insurance coverage for CGMs in the U.S. is improving, especially for intensive insulin users, with private insurers beginning to extend coverage to non-insulin users [9] - Medicare currently restricts CGM coverage to insulin users, but advocacy efforts may lead to policy changes in the future [9]